| Targeted therapy for locally advanced renal cell carcinoma. | |
| | |
MedLine Citation:
|
PMID: 20625844 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
A number of molecularly targeted agents are now available for patients with metastatic renal cell carcinoma. Their role in locally advanced disease is not well defined, and the mechanisms of progression in the high-risk patient are poorly understood. For an agent to be effective in locally advanced renal cell carcinoma it needs to be able to downstage primary tumors, and to prevent the formation of metastases. In this review, we summarize clinical trials assessing the ability of these new agents to cytoreduce primary tumors, and explore available evidence on their ability to prevent the formation of metastases. Ongoing adjuvant clinical trials assessing molecularly targeted agents in the high-risk setting will provide valuable information on their utility in this patient population. Future trials using agents with optimized cytoreductive capabilities in conjunction with therapies capable of preventing metastatic dissemination may improve the outcomes of patients with locally advanced renal cell carcinoma. |
| | |
Authors:
|
Eric Jonasch; Nizar M Tannir |
Related Documents
:
|
20684104 - Gypsies as victims of the holocaust. 20966334 - Management of hypersplenism by partial splenic embolization with ethylene vinyl alcohol... 6358134 - Intraarterial chemotherapy for head and neck cancer, part 1: theoretical considerations... 20523084 - Metastatic colorectal cancer: from improved survival to potential cure. 11284494 - Treatment of multiple evanescent white dot syndrome with cyclosporine. 447984 - Survival in the elderly with acute leukemia. |
Publication Detail:
|
Type: Journal Article Date: 2010-07-14 |
Journal Detail:
|
Title: Targeted oncology Volume: 5 ISSN: 1776-260X ISO Abbreviation: Target Oncol Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-08-30 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101270595 Medline TA: Target Oncol Country: France |
Other Details:
|
Languages: eng Pagination: 113-8 Citation Subset: IM |
Affiliation:
|
The University of Texas M. D. Anderson Cancer Center, GU Medical Oncology- Unit 1374, PO Box 301439, Houston, TX 77230-1439, USA. ejonasch@mdanderson.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Assessing the volume-outcome hypothesis and region-level quality improvement interventions: pancreas...
Next Document: Targeted therapies in renal cell cancer: recent developments in imaging.